Here is My Question:
What are the possibilities and effectiveness for the new DMT “BTK inhibitors” being developed? Are there any studies that someone in San Diego might be able to sign up for? For those already on BCell depleters like Rituxan or Ocrevus, would they eventually be able to take a BTKi? How far off do you think we might be in seeing this drug come out?
BTK, which stands for Bruton Tyrosine Kinase, inhibitors are a promising new class of treatment capable of regulating B cells and microglial activity in the central nervous system without depleting or destroying these cells. There are many phase III studies underway for both relapsing MS, Secondary Progressive MS and Primary Progressive MS. Preliminary phase II studies in relapsing MS showed significant effects on MRI activity and no unusual or serious safety concerns. Phase II studies are required before moving on to phase III studies which determine the clinical effectiveness and safety of a drug in a larger number of people with MS.
Tolebrutinib, a BTK inhibitor made by Sanofi, is furthest along in development with results possibly available in 2023.
UCSD is recruiting relapsing patients for a trial of Evobrutinib (a BTK inhibitor made by Merck) and progressive (both secondary and primary) patients for trials of Tolebrutinib.
If you go to the Clinicaltrials.gov web site you can look up any MS clinical trial and find out how to obtain information on possible participation and the location of study sites.
Revere P (Rip) Kinkel, MDProfessor of Clinical Neurosciences
Director of the Multiple Sclerosis Program
Clinical Neurosciences Director
University of California San Diego
PLEASE NOTE: This information/opinions on this site should be used as an information source only. This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.